

AMS HEALTH SCIENCES INC
Form 10QSB
May 11, 2007

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 10-QSB

**(X) QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934**

For the quarterly period ended March 31, 2007

or

**() TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934**

For the transition period from _____ to _____

Commission File Number: 001-13343

AMS HEALTH SCIENCES, INC.

(Exact name of Small Business Issuer as specified in its charter)

Oklahoma

(State or other jurisdiction of incorporation or organization)

73-1323256

(I.R.S. Employer Identification No.)

711 NE 39th Street

Oklahoma City, Oklahoma 73105

(Address of principal executive offices)

(405) 842-0131

(Issuer's telephone number, including area code)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes X No

Indicate by check mark whether the issuer is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No X

On May 10, 2007 we had outstanding 8,515,824 shares of our common stock, \$0.0001 par value.

Transitional Small Business Disclosure Format (check one):

Yes No X

AMS HEALTH SCIENCES, INC.
QUARTERLY REPORT ON FORM 10-QSB
FOR THE THREE MONTHS ENDED MARCH 31, 2007

Table of Contents

	Report of Independent Registered Public Accounting	
Part I Financial Information		3
Item 1. Financial Statements		3
Consolidated Balance Sheets		3
Consolidated Statements of Operations		4
Consolidated Statements of Cash Flows		5
Notes to Consolidated Financial Statements		6
Report of Independent Registered Public Accounting Firm		20
Item 2. Management's Discussion and Analysis or Plan of Operation		21
Item 3. Controls and Procedures		28
Part II -Other Information		29
Item 1. Legal Proceedings		29
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		29
Item 3. Defaults Upon Senior Securities		29
Item 4. Submission of Matters to a Vote of Security Holders		29
Item 5. Other Information		29
Item 6. Exhibits		30

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain statements under the caption "Item 2 - Management's Discussion and Analysis or Plan of Operation" constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Certain, but not necessarily all, of such forward-looking statements can be identified by the use of forward-looking terminology such as "anticipates", "believes", "expects", "may", "will", or "should" or other variations thereon, or by discussions of strategies that involve risks and uncertainties. Our actual results or industry results may be materially different from any future results expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include general economic and business conditions; our ability to implement our business and acquisition strategies; changes in the network marketing industry and changes in consumer preferences; competition; availability of key personnel; increasing operating costs; unsuccessful advertising and promotional efforts; changes in brand awareness; acceptance of new product offerings; changes in, or the failure to comply with, government regulations (especially food and drug laws and regulations); product liability matters; our ability to obtain financing for future acquisitions and other factors. We do not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statements were made.

PART I - FINANCIAL INFORMATION

Item 1. **FINANCIAL STATEMENTS**

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
MARCH 31, 2007 AND DECEMBER 31, 2006

ASSETS	March 31, 2007 (Unaudited)	December 31, 2006
CURRENT ASSETS:		
Cash	\$ 223,388	\$ 269,726
Marketable securities, available for sale, at fair value	500,000	793,183
Receivables	16,653	44,576
Inventory, net	853,262	700,664
Other assets	77,368	77,319
Current assets of discontinued operations	56,025	110,521
Total current assets	1,726,696	1,995,989
RESTRICTED SECURITIES	79,628	78,723
RECEIVABLES	28,994	28,374
PROPERTY AND EQUIPMENT, net	2,684,450	2,794,393
COVENANTS NOT TO COMPETE and other intangibles, net	305,099	324,553
OTHER ASSETS	412,957	457,344
NONCURRENT ASSETS OF DISCONTINUED OPERATIONS	1,207,926	1,253,480
TOTAL	\$ 6,445,750	\$ 6,932,856
LIABILITIES AND STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accounts payable	\$ 724,474	\$ 559,920
Accrued commissions and bonuses	265,761	268,717
Accrued other expenses	235,553	400,204
Accrued sales tax liability	235,013	200,481
Deferred compensation	97,129	96,378
Notes payable	507,542	257,542
Capital lease obligations	97,393	104,591
Current liabilities of discontinued operations	302,336	360,582
Total current liabilities	2,465,201	2,248,415
LONG-TERM LIABILITIES:		
Notes payable	480,096	625,220
Capital lease obligations	73,418	95,527
Deferred compensation	259,012	281,101
Lease abandonment liability	5,158	55,123
Liabilities of discontinued operations	1,489,712	1,570,359
Total liabilities	4,772,597	4,875,745
COMMITMENT AND CONTINGENCIES (Note 8)		
STOCKHOLDERS' EQUITY		
Common stock - \$.0001 par value; authorized 495,000,000 shares; issued 9,107,419 and 9,107,419 shares; outstanding 8,515,824 and 8,515,824 shares, respectively	905	905

Edgar Filing: AMS HEALTH SCIENCES INC - Form 10QSB

Paid-in capital	23,636,243	23,609,734
Notes receivable for exercise of options	(31,000)	(31,000)
Accumulated deficit	(19,300,216)	(18,889,749)
Total capital and accumulated deficit	4,305,932	4,689,890
Less cost of treasury stock (591,595 shares)	(2,632,779)	(2,632,779)
Total stockholders' equity	1,673,153	2,057,111
TOTAL	\$ 6,445,750	\$ 6,932,856

See notes to consolidated financial statements.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE PERIODS ENDED MARCH 31, 2007 AND 2006
(UNAUDITED)

	Three Months Ended	
	March 31,	
	2007	2006
Net sales	\$ 2,435,342	\$ 2,425,474
Cost of sales	1,556,705	1,565,154
Gross profit	878,637	860,320
Marketing, distribution and administrative expenses:		
Marketing	282,996	141,144
Distribution and administrative	897,465	689,520
Total marketing, distribution and administrative expenses	1,180,461	830,664
Income (loss) from operations	(301,824)	29,656
Other income (expense):		
Interest and dividends, net	(143,174)	3,842
Other, net	27,005	59,664
Total other income (expense)	(116,169)	63,506
Income (loss) from continuing operations before taxes	(417,993)	93,162
Income tax expense (benefit)	-	-
Income (loss) from continuing operations	(417,993)	93,162
Discontinued operations (Note 11)		
Income (loss) from discontinued operations, net of tax	7,654	(335,715)
Net loss	\$ (410,339)	\$ (242,553)
Net loss per share:		
Basic:		
Income (loss) from continuing operations	\$ (0.05)	\$ 0.01
Income (loss) from discontinued operations net of tax	-	(0.04)
Net loss per share	\$ (0.05)	\$ (0.03)
Diluted:		
Income (loss) from continuing operations	\$ (0.05)	\$ 0.01
Income (loss) from discontinued operations net of tax	-	(0.04)
Net loss per share	\$ (0.05)	\$ (0.03)
Shares used in computing net loss per share:		
Basic	8,515,824	7,766,574
Diluted	8,515,824	7,766,574

See notes to consolidated financial statements.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006
(UNAUDITED)

	Three Months Ended	
	March 31,	
	2007	2006
CASH FLOWS FROM OPERATING ACTIVITIES		
Net Loss	\$ (410,339)	\$ (242,553)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities		
Net (income) loss from discontinued operations	(7,654)	335,715
Depreciation and amortization	188,922	164,859
Amortization of note valuation discount	104,877	-
Bad debt recovery	(1,452)	(11,319)
Stock option compensation expense	26,509	2,937
Gain on sale of assets	-	(46,617)
Gain on lease cancellation	(120,755)	-
Realized gain on sale of marketable securities	-	(234)
Changes in operating assets and liabilities:		
Receivables	26,686	(15,379)
Inventory	(152,598)	215,240
Other assets	3,930	850
Accounts payable and accrued expenses	132,700	(127,491)
Lease abandonment liability	(30,561)	(17,007)
Deferred compensation	(21,337)	(23,594)
Net operating activities of discontinued operations	39,404	(95,899)
Net cash provided by (used) in operating activities	(221,668)	139,508
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of property and equipment	(19,118)	(97,822)
Sales of property and equipment	-	47,950
Receipts on notes receivable	2,070	10,412
Purchase of marketable securities, available for sale	(8,336)	(281,450)
Sales marketable securities, available for sale	300,613	404,452
Net investing activities of discontinued operations	12,756	-
Net cash provided by investing activities	287,985	83,542
CASH FLOWS FROM FINANCING ACTIVITIES:		
Bank overdrafts	-	(203,500)
Principal payment on capital lease obligations	(29,306)	(30,228)
Net financing activities of discontinued operations	(83,350)	(34,809)
Net cash used in financing activities	(112,656)	(268,537)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(46,339)	(45,487)

CASH AND CASH EQUIVALENTS, BEGINNING		269,727		118,805
CASH AND CASH EQUIVALENTS, ENDING	\$	223,388	\$	73,318

See notes to consolidated financial statements.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006
(UNAUDITED)**

1. UNAUDITED INTERIM FINANCIAL STATEMENTS

The unaudited consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. The accompanying consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements of the Company, and notes thereto, for the year ended December 31, 2006.

The information furnished reflects, in the opinion of management, all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the results of the interim periods presented. Operating results of the interim period are not necessarily indicative of the amounts that will be reported for the year ending December 31, 2007.

2. SHARE-BASED COMPENSATION

On January 1, 2006, the Company adopted Statement of Financial Accounting Standards No. 123 (revised 2004), "Share-Based Payment", ("SFAS 123R") which requires the measurement and recognition of compensation expense based on estimated fair values for all share-based payment awards made to employees and directors, including employee stock options. SFAS 123R supersedes the Company's previous accounting under Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees" ("APB 25") for periods beginning in 2006. In March 2005, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 107 ("SAB 107") relating to SFAS 123R. The Company has utilized the guidance of SAB 107 in its adoption of SFAS 123R.

Equity Compensation Plans

During 1995, the Company approved the 1995 Stock Option Plan (the "Plan"). Under this Plan, options available for grant can consist of (i) nonqualified stock options, (ii) nonqualified stock options with stock appreciation rights attached, (iii) incentive stock options, and (iv) incentive stock options with stock appreciation rights attached. The Company has reserved 1,125,000 shares of the Company's common stock \$.0001 par value, for the Plan. The Plan limits participation to employees, independent contractors and consultants. Non-employee directors are excluded from Plan participation. The option price for shares of stock subject to this Plan is set by the Stock Option Committee of the Board of Directors at a price not less than 85% of the market value of the stock on the date of grant. No stock options may be exercised within nine months from the date of grant, unless under a Plan exception, nor more than ten years after the date of grant. The Plan provides for the grant of stock appreciation rights, which allow the holder to receive in cash, stock or combination thereof, the difference between the exercise price and the fair value of the stock at date of exercise. The fair value of stock appreciation rights is charged to compensation expense. The stock appreciation right is not separable from the underlying stock option or incentive stock option originally granted and can only be exercised in tandem with the stock option. No stock appreciation rights are attached to any options outstanding. At March 31, 2007, no shares were available for future grants under the 1995 Stock Option Plan. Options granted under the Plan have an exercise price equal to the fair market value on the date of grant, are fully vested at March 31, 2007, and generally expire ten years after grant date.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006
(UNAUDITED)**

During 2003, the Company approved the 2003 Stock Incentive Plan, or 2003 Plan. Under the 2003 Plan, options available for grant can consist of (i) nonqualified stock options, (ii) incentive stock options, and (iii) restricted stock. The Company has reserved 2,000,000 shares of the Company's common stock \$.0001 par value for the 2003 Plan. The Plan limits participation to employees, independent contractors, and consultants. The option price for shares of stock subject to this Plan is set by the Compensation Committee of the Board of Directors at a price not less than market value of the common stock on the date of grant. No stock options may be exercised within six months from the date of grant, unless under a Plan exception, nor more than ten years after the date of grant. At March 31, 2007, no shares were available for future grants under the 2003 Stock Incentive Plan. Options granted under the Plan have an exercise price equal to the fair market value on the date of grant, are fully vested at March 31, 2007, and generally expire ten years after grant date.

During 2006, the Company approved the 2006 Long-Term Incentive Plan ("the Plan"). Under the Plan, options available for grant can consist of (i) nonqualified stock options, (ii) incentive stock options, (iii) restricted stock, (iv) stock appreciation rights, and (v) performance units. The Company has reserved 5,000,000 shares of the Company's common stock \$.0001 par value for the Plan. The Plan limits participation to employees and non-employee Directors. The option price for shares of stock subject to this Plan is set by the Compensation Committee of the Board of Directors at a price not less than market value of the common stock on the date of grant. No stock options may be exercised more than ten years after the date of grant.

Grant-Date Fair Value

The Company uses the Black-Scholes option pricing model to calculate the grant-date fair value of an award. The fair value of options granted during the first quarter of 2007 and 2006 were calculated using the following estimated weighted average assumptions:

	Three Months Ended	
	March 31,	
	2007	2006
Expected volatility	79.34%	74.49%
Expected term (in years)	5	5
Risk-free interest rate	4.39%	4.80%
Expected dividend yield	0%	0%

Expected volatility is based on historical volatility. The expected term of the options is based on management's best estimate. The risk-free interest rate is based on the yield on zero-coupon U.S. Treasury securities for a period that is commensurate with the expected term assumption. The Company has not historically issued any dividends and does not expect to in the future.

Share-Based Compensation Expense

The Company uses the straight-line attribution method to recognize expense for unvested options. The amount of share-based compensation recognized during a period is based on the value of the awards that are ultimately expected to vest. SFAS 123R requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company will re-evaluate the forfeiture rate annually and adjust as necessary.

Share-based compensation expense recognized under SFAS 123R for the three months ended March 31, 2007 and 2006 was \$26,509, and \$2,937, respectively.

-7-

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006
(UNAUDITED)**

Option Activity

A summary of the activity under the Company's stock options plans for the three-month period ended March 31, 2007 is presented below:

	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Options outstanding at December 31, 2006	2,715,009	\$ 2.42		
Granted	50,000	\$ 0.65		\$ 1,000
Exercised	-	-		-
Expired	(2,000)	\$ 2.00		-
Canceled	-	-		-
Options outstanding at March 31, 2007	2,763,009	\$ 2.39	4.54	\$ 13,000
Option exercisable at March 31, 2007	2,113,009	\$ 3.11	3.91	\$ -
Options vested and options expected to vest at March 31, 2007	2,763,009	\$ 2.39	4.54	\$ -

*The Company's CEO, Jerry Grizzle was granted 250,000 stock options in 2006 as an incentive to join the Company. These options were outside a Company Incentive Plan.

The total grant-date fair value of stock options that became fully vested during the three months ended March 31, 2007 was \$26,509. As of March 31, 2007 there was \$207,738 of total unrecognized compensation cost, net of tax and estimated forfeitures, related to unvested share-based awards, which is expected to be recognized over a period of 4.25 years.

3. MARKETABLE SECURITIES

Securities are classified as available for sale with the related unrealized gains and losses excluded from earnings and reported net of income tax as a separate component of stockholders' equity until realized. Realized gains and losses on sales of securities are based on the specific identification method. Declines in the fair value of investment securities below their carrying value that are other than temporary are recognized in earnings.

4. RESTRICTED INVESTMENTS

In connection with the Heartland Cup acquisition, the Company has pledged marketable securities in the amount of \$79,268 as restricted cash against one of the notes payable.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006
(UNAUDITED)**

5. DEBT

The secured financing consists of the following at March 31, 2007 and December 31, 2006:

	March 31, 2007	December 31, 2006
Laurus term note	\$ 2,000,000	\$ 2,000,000
Partial conversion, issuance of 350,000 shares	(159,125)	(159,125)
Valuation discount	(1,176,904)	(1,176,904)
Accretion of discount to interest expense	323,668	218,791
Total secured financing	\$ 987,638	\$ 882,762
Current	\$ 507,542	\$ 257,542
Long-term	\$ 480,096	\$ 625,220

On June 28, 2006, the Company entered into a series of agreements with Laurus Master Fund, Ltd. (“Laurus”) whereby the Company issued to Laurus (i) a secured convertible term note (“Note”) in the principal amount of \$2,000,000, and (ii) a warrant (“Warrant”) to purchase up to 2,272,727 shares of the Company’s common stock at a price of \$0.53 per share. Out of the loan proceeds, the Company agreed to pay the sum of \$74,000 to Laurus Capital Management, LLC, the investment advisor to Laurus, the sum of \$27,500 to Laurus Capital Management, LLC as reimbursement for its due diligence and legal fees and expenses incurred in connection with the transaction, and the sum of \$1,500 to Loeb & Loeb LLP, the escrow agent for Laurus. Total closing costs were \$103,000.

The principal amount of the Note bears interest at a per annum rate equal to the prime rate (as published in the Wall Street Journal from time to time) plus three percent (3.0%); provided, however that the interest rate may not be less than ten percent (10.0%). At March 31, 2007, the interest rate was 11.25%. Interest payments are due monthly beginning July 1, 2006. Principal payments in the amount of \$83,333 are due monthly beginning July 1, 2007. The final maturity date of the Note is June 28, 2009 (the “Maturity Date”). Interest expense related to the note was \$51,775 for the three months ended March 31, 2007.

The principal amount of the Note and accrued interest thereon is convertible into shares of the Company’s common stock at a price of \$0.51 per share, subject to anti-dilution adjustments. Under the terms of the Note, the monthly payments of interest and/or principal (the “Monthly Amount”) due on the Note are payable in shares of the Company’s common stock if the following criteria are met: (i) the average closing price of the Company’s common stock for the five (5) days preceding the payment date is greater than or equal to 11.5% of the Fixed Conversion Price (defined below) and (ii) the amount of such conversion does not exceed twenty five percent (25%) of the aggregate dollar trading volume of the Company’s common stock for the period of twenty-two trading days immediately preceding such payment date. If subsection (i) above is met but subsection (ii) above is not met as to the entire Monthly Amount, then Laurus is required to convert only such part of the Monthly Amount that meets the criteria of subsection (ii). The Company has agreed to register all of the shares that are issuable upon conversion of the Note and exercise of the 2,272,727 Warrants. The Company has granted Laurus a right of first refusal with respect to any debt or equity financings.

The Company calculated that the fair value of the Warrants issued to Laurus was \$588,452 based upon the relative value of the Black-Scholes valuation of the warrants and the underlying debt amount. The Company determined that

the beneficial conversion feature (“BCF”) of the Note was \$588,452. The value of the Warrants issued to Laurus of \$588,452 and the \$588,452 of calculated BCF have been reflected by the Company as a valuation discount and offset to the face amounts of the Note.

-9-

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006
(UNAUDITED)**

The valuation discount will be amortized into interest expense over the three-year term of the Note using the effective interest method. Amortization of discounts for the conversion feature and the Warrants resulted in charges to interest expense totaling \$104,878 for the three months ended March 31, 2007.

In conjunction with the financing, the Company also incurred fees to various investment advisors that facilitated the transaction. These fees totaled \$287,500, of which \$127,500 was paid through the issuance of 250,000 shares of the Company's common stock. In addition, the Company issued these advisors warrants to purchase 495,543 shares of common stock at a price of \$0.51 per share. The Company calculated that the fair value of the warrants issued to the advisors was \$130,770 based upon the relative value of the Black-Scholes valuation of the warrants and the underlying debt amount. The closing costs, fees paid to the advisors and the value of the warrants issued to the advisors have been reflected as deferred financing costs in the accompanying balance sheet and are being amortized over the life of the loan. Amortization of the deferred financing costs related to the note totaled \$43,439 for the three months ended March 31, 2007.

6.

LOSS PER SHARE

Loss per common share - basic is computed based upon net loss divided by the weighted average number of common shares outstanding during each period. Loss per common share - assuming dilution is computed based upon net loss divided by the weighted average number of common shares outstanding during each period adjusted for the effect of dilutive potential common shares calculated using the treasury stock method.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006
(UNAUDITED)**

The following is a reconciliation of the common shares used in the calculations of loss per common share - basic and loss per common share - assuming dilution:

	Income (Loss)	Shares	Per Share
	(Numerator)	(Denominator)	Amount
Weighted average common shares outstanding:			
For the three months ended March 31, 2007:			
Loss per common share:			
Loss available to common stockholders	\$ (410,339)	8,515,824	\$ (0.05)
Loss per common share - assuming dilution:			
Options	-	-	
Loss available to common stockholders plus assumed conversions	\$ (410,339)	8,515,824	\$ (0.05)
For the three months ended March 31, 2006:			
Loss per common share:			
Loss available to common stockholders	\$ (242,553)	7,766,574	\$ (0.03)
Loss per common share - assuming dilution:			
Options	-	-	
Loss available to common stockholders plus assumed conversions	\$ (242,553)	7,766,574	\$ (0.03)

Options to purchase 2,763,009 shares of common stock at exercise prices ranging from \$0.51 to \$6.00 per share were outstanding for the three months ended March 31, 2007, but were not included in the computation of income (loss) per common share - assuming dilution because there was a net loss for the period then ended and inclusion of such options is anti-dilutive.

Options to purchase 2,200,009 shares of common stock at exercise prices ranging from \$.62 to \$6.00 per share were outstanding for the three months ended March 31, 2006, but were not included in the computation of income (loss) per common share - assuming dilution because there was a net loss for the period then ended and inclusion of such options is anti-dilutive.

7.**DEFERRED TAXES**

On a regular basis, management evaluates all available evidence, both positive and negative, regarding the ultimate realization of the tax benefits of its deferred tax assets. Valuation allowances have been established for certain operating loss and credit carryforwards that reduce deferred tax assets to an amount that will, more likely than not, be realized. Uncertainties that may affect the realization of these assets include tax law changes and the future level of product prices and costs. The outlook for determination of this allowance is calculated on the Company's historical taxable income, its expectations for the future based on a rolling twelve quarters, and available tax-planning strategies. Based on this determination, management does not expect that the net deferred tax assets will be realized as offsets to reversing deferred tax liabilities and as offsets to the tax consequences of future taxable income. As such, a valuation allowance was provided for the entire deferred tax asset of approximately \$6,000,000 at March 31, 2007. The

Company's effective tax rate differs from its statutory tax rate for the three months ended March 31, 2007 and 2006, due to the tax valuation allowance. The Company has net operating loss carryforwards of approximately \$14,000,000 available to reduce future taxable income, which will begin to expire in 2021.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006
(UNAUDITED)**

8. COMMITMENTS, CONTINGENCIES AND GUARANTEES

Recent Regulatory Developments - As a marketer of products that are ingested by consumers, the Company is subject to the risk that one or more of the ingredients in its products may become the subject of adverse regulatory action. For example, one of the ingredients in the Company's prior AM-300 product was ephedra, an herb that contains naturally-occurring ephedrine alkaloids. The Company's manufacturer used a powdered extract of that herb when manufacturing AM-300. The Company marketed AM-300 principally as an aid in weight management. The extract was an 8% extract, which means that every 100 milligrams of the powdered extract contains approximately eight milligrams of naturally occurring ephedrine alkaloids.

On February 11, 2004, the FDA issued and published in the Federal Register its final rule on ephedrine-containing supplements, stating that since an "unreasonable risk" had been determined, such supplements would be considered "adulterated" under the Federal Food, Drug, and Cosmetic Act, or FFDC, and thus may not be sold. In essence, this final rule (or regulation) imposed a national ban on ephedrine supplements. The effective date of this regulation was April 12, 2004. The Company complied with the new regulation and ceased all sales and advertisement of AM-300 and any other ephedra-containing supplement as of April 12, 2004. The FDA has continuously and vigilantly enforced this total ban on ephedra-containing supplements.

For the future, the FDA and also Congress have indicated that they will consider whether alternatives to ephedra, other weight loss and energy stimulants (such as bitter orange), similarly carry an unreasonable risk to the central nervous system, and thus to human health. These proposals to limit stimulant ingredients, if finalized, may necessitate reformulations of some of the Company's weight loss products.

Product Liability - Also, in the aftermath of the ephedra ban, on April 22, 2004, in comments before a scientific meeting, then Acting FDA Commissioner, Lester Crawford, outlined what an FDA press release termed a "science-based plan for dietary supplement enforcement". The press release went on to say that the agency "would soon provide further details about its plan to ensure that the consumer protection provisions of DSHEA are used effectively and appropriately". Referring to its recent rulemaking on ephedra, the FDA also stated that it "expects to evaluate the available pharmacology, published literature ..., evidence-based reviews, and adverse event information" of "individual dietary supplements". Soon afterwards, this promised FDA document was issued, with the title "Regulatory Strategy for the Further Implementation and Enforcement of the Dietary Supplement Health and Education Act of 1994". No new regulations or proposed rules pursuant to this strategy have yet been issued, except that the FDA has recently welcomed and received comments from the industry for a better procedure for the FDA to review a company's safety information as to a new dietary ingredient, or NDI, in an NDI Notification. The final guidance document concerning NDI Notifications has not yet been issued by the FDA. At this time, NDI Notifications are not required for any AMS products.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006
(UNAUDITED)**

Anti-DSHEA Proposed Legislation. Finally, as the press, the FDA, and members of Congress and of the supplement industry have all predicted, the very issuance of the final rule (ban) on ephedra has caused Congress to rethink the Dietary Supplement Health and Education Act of 1994, or DSHEA, specifically as to how safety in supplements may be ensured, and also as to whether specific categories of dietary ingredients should not be permitted at all. In particular, there is growing sentiment (including from one herbal trade association) to make Adverse Event Reporting (AERs) mandatory for all manufacturers and marketers of dietary supplements, so that the FDA may take action more quickly than it did on ephedra, when a harmful herb or other ingredient is suspected. Since February 2003, there have been several bills proposed in Congress that would amend DSHEA, make safety safeguards stricter, even approaching the rigor and reporting required for FDA-regulated drugs. Some examples are as follows:

S. 722 - The Dietary Supplement Safety Act was introduced by Senator Richard Durbin in March 2003, and would greatly undermine DSHEA, especially Section 4 regarding safety, giving the FDA new powers of oversight and blanket authority over whole categories of supplements, including stimulants. Stimulants are used in many weight loss products, including some of our supplements. To the best of our knowledge, this bill and the bill described below (though perhaps under different numbers) are still pending.

H.R. 3377: Beginning on October 28, 2003, Senator McCain chaired Senate Hearings on whether DSHEA adequately protects consumers. Also on October 28, Cong. Susan Davis and Cong. Henry Waxman introduced The Dietary Supplement Access and Awareness Act, H.R. 3377, purporting to be about safety and access for consumers to supplements, but actually recommending severe restrictions and dramatic redefinitions of what constitutes a dietary supplement. This bill would impose several requirements for supplements, including unprecedented FDA pre-approval as well as strict AER reporting, and excludes only vitamins and minerals from such new requirements. Like S. 722, this bill would reverse the safety burden of proof in Section 4 of DSHEA (one of the industry's victories in 1994), and instead require the manufacturer to demonstrate safety, rather than the burden being on the FDA to show "imminent hazard" or "unreasonable risk".

So far, neither of the bills above, nor any other proposed legislation that would undermine DSHEA or impose additional requirements on supplements, have passed. With the help of their regulatory attorney, the company will continue to monitor these anti-DSHEA bills, and determine if any of them become a serious threat to our business. In addition, the two major trade associations of the dietary supplement industry—the American Herbal Products Association, or AHPA, and the National Natural Foods Association, or NNFA—have both been actively lobbying against any bills that would require or lead to unreasonable restraints on the manufacture, labeling, and marketing of dietary supplements.

Product Liability - AMS, like other marketers of products that are intended to be ingested, face an inherent risk of exposure to product liability claims in the event that the use of their products results in injury. We have limited product liability insurance with coverage limits of \$1.0 million per occurrence and \$2.0 million aggregate. All of AMS' product manufacturers carry product liability insurance, which covers the Company's products. Such product claims against the Company could adversely affect product sales, results of their operations, financial condition and the value of common stock.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006
(UNAUDITED)**

Legal Proceedings - The Company is currently involved in asserted and unasserted claims, which arise in the ordinary course of business. The Company routinely evaluates whether a loss is probable, and if so, whether it can be estimated. Estimates are based on similar case law matters, consultation with subject matter experts and information obtained through negotiations with counter-parties. As such, accurately depicting the outcome of pending litigation requires considerable judgment and is subject to material differences on final settlement. Accruals for probable losses are recorded in accrued expenses. If the Company's assessment of the probability is inaccurate, the Company may need to record additional accruals or reduce recorded accruals later. In addition, the Company may need to adjust its estimates of the probable loss amounts as further information is obtained or the Company considers settlements. See "Part II, Item 1. Legal Proceedings" for a description of the most significant claims by or against the Company.

Employment Agreements - In January 2006, the Company entered into a written employment agreement with Jerry W. Grizzle, the Company's Chairman of the Board, President and Chief Executive Officer. The contract is for a two-year term, commencing January 25, 2006, followed by two successive one-year terms. On April 2, 2007, the board of directors extended the term of Jerry Grizzle's employment agreement from January 25, 2008 to January 25, 2010. Mr. Grizzle's base salary is \$150,000 per year for the first year of the Initial Term, \$200,000 for the second year of the Initial Term and \$250,000 for each year after the Initial Term. Additionally, Mr. Grizzle will be eligible to receive certain performance-based incentive bonuses. The Company granted Mr. Grizzle options to purchase 250,000 shares of the Company's common stock on February 15, 2006, with an exercise price of \$0.62 per share, which was the closing price of the Company's common stock on that day. The options vest in five equal annual installments beginning February 15, 2007, and expire February 15, 2016. In the event the Company terminates Mr. Grizzle without cause, he will receive certain severance pay based upon his length of employment with the Company.

In April 2006, the Company entered into a written employment agreement with Robin L. Jacob, the Company's Vice President, Secretary, Treasurer and Chief Financial Officer. The contract is for a two-year term, commencing February 12, 2006, followed by two successive one-year terms unless either party elects not to renew the Agreement. Ms. Jacob's base salary is \$100,000 per year for the first year of the Initial Term, \$112,500 for the second year of the Initial Term and \$125,000 for each year after the Initial Term. Additionally, she is eligible to receive certain performance-based incentive bonuses. The Company granted Ms. Jacob options to purchase 150,000 shares of the Company's common stock at an exercise price of \$0.64 per share, which was the closing price of the Company's common stock on March 31, 2006, the last trading day prior to the date the options were granted. The options vest in five equal annual installments beginning April 1, 2007, and expire April 1, 2016. In the event the Company terminates Ms. Jacob without cause, she will receive certain severance pay based upon her length of employment with the Company.

In September 2006, the Company entered into a written employment agreement with Dennis P. Loney, the Company's Vice President of Operations. The contract is for a two-year term, commencing September 19, 2006, followed by two successive one-year terms unless either party elects not to renew the Agreement. Mr. Loney's base salary is \$106,000 per year for the first year of the Initial Term, \$112,500 for the second year of the Initial Term and \$125,000 for each year after the Initial Term. Additionally, he is eligible to receive certain performance-based incentive bonuses. The Company granted Mr. Loney options to purchase 150,000 shares of the Company's common stock at an exercise price of \$0.63 per share, which was the closing price of the Company's common stock on that day. The options vest in five equal annual installments beginning September 19, 2007, and expire September 19, 2016. In the event the Company terminates Mr. Loney without cause, he will receive certain severance pay based upon his length of employment with the Company.

9. DEFERRED COMPENSATION

In connection with the November 4, 2005 extension of Mr. Hail's employment agreement, Mr. Hail's monthly variable salary ceased and was replaced by a fixed supplemental payment, in a gross amount necessary to cover all federal, state, and local taxes and all employment taxes and to pay a net amount of \$7,000 per month.

-14-

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006
(UNAUDITED)**

In 2003, the Company made an accrual for the discounted value of the fixed supplemental payments as a distribution and administrative expense. At March 31, 2007, the discounted value of those fixed supplemental payments was approximately \$356,000. The Company accrues the expense in distribution and administrative expenses. On February 16, 2006, the Company announced Mr. Hail's retirement as Chief Executive Officer and Chairman of the Board.

10. LEASE ABANDONMENT

In January 2004, the Company commenced a relocation of its corporate headquarters from 2601 NW Expressway (the Oil Center), Oklahoma City, Oklahoma to its warehouse and distribution facility. A portion of the Oil Center was maintained for storage, a portion was maintained for possible relocation of Company personnel due to expansion of the business and a portion was subleased to a third party under a short-term lease. In September 2004, the Company purchased an existing building adjacent to its corporate headquarters to be used for additional office, warehouse and storage space. Company management believes the purchased building is sufficient to meet expansion needs, and as such, abandoned the Oil Center location. In determining lease abandonment, management assumed the continuation of the existing sublease at the current rate. In addition, a discount rate of 6.5% was used to calculate the present value of current lease payments less sublease revenue. At March 31, 2007, the lease abandonment accrual was approximately \$36,000.

11. DISCONTINUED OPERATIONS

On September 9, 2005 the Company entered into a definitive Stock Purchase Agreement with Heartland Cup, Inc. ("Heartland Cup") and its principal shareholder for the purchase of all of the principal shareholder's stock in Heartland Cup. Upon closing of the Stock Purchase Agreement, the Company acquired 2,000,000 shares, or approximately 83% of the outstanding capital stock of Heartland Cup, for 200,000 shares of the Company's common stock. In addition, the Company paid approximately \$200,000 to acquire the remaining shares of Heartland Cup.

On March 31, 2006, the Company adopted a plan to discontinue the operations of its Heartland Cup subsidiary. On November 15, 2006, the Company entered into certain lease and purchase agreements with Republic Plastics Ltd. ("Republic") allowing Republic to take over operation of the Heartland Cup plant immediately. Republic produces Styrofoam products for private label users. Pursuant to the agreements, and effective November 15, 2006, Republic assumed the existing lease for the Heartland Cup plant, purchased all remaining cup contracts with Heartland customers, and executed a two-year equipment lease. The equipment lease includes an option in favor of Republic Plastics to purchase all the equipment utilized in the Heartland Cup operations at a specified price. The option period begins November 15, 2007 and ends November 15, 2008.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006
(UNAUDITED)**

The results of operations of discontinued operations for the three months ended March 31, 2007 and 2006 are summarized below:

	Three Months Ended	
	March 31,	
	2007	2006
Net sales	\$ 1,931	\$ 513,445
Other income - lease revenue	78,000	-
Revenues	\$ 79,931	\$ 513,445
Income (loss) from operations of discontinued operations	\$ 7,654	\$ (315,715)
Estimated cost to sell	-	(20,000)
Income tax effect	-	-
Loss from operations of discontinued operations, net of tax	\$ 7,654	\$ (335,715)

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006
(UNAUDITED)**

The components of assets and liabilities of discontinued operations in the accompanying consolidated balance sheets are as follows:

	March 31,	
	2007	2006
Current assets of discontinued operations:		
Cash	\$ 1,252	\$ 1,113
Accounts Receivable	16,560	171,933
Inventory	38,213	203,931
Total	\$ 56,025	\$ 376,977
Noncurrent assets of discontinued operations:		
Other assets	\$ 5,092	\$ 471
Property and equipment, net	1,202,834	1,347,977
Total	\$ 1,207,926	\$ 1,348,448
Current liabilities of discontinued operations:		
Accounts payable	\$ 13,933	\$ 227,225
Current portion of long-term debt	293,774	444,434
Other current liabilities	22,495	30,656
Total	\$ 302,336	\$ 702,315
Long-term liabilities of discontinued operations:		
Long-term debt	\$ 1,485,134	\$ 1,607,626

12. RECENT ACCOUNTING PRONOUNCEMENTS

In June 2006, the FASB issued interpretation No. 48, Accounting for Uncertainty in Income Taxes—an Interpretation of FASB statement No. 109, (“FIN 48”). FIN 48 clarifies the accounting for uncertainty in income taxes recognized in a company’s financial statements in accordance with SFAS No. 109, Accounting for Income Taxes. FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. FIN 48 is effective for fiscal years beginning after December 15, 2006. The Company has evaluated the impact of FIN 48 as of the January 1, 2007 adoption date and determined there will be no impact to its financial statements.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006
(UNAUDITED)**

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements." SFAS No. 157 clarifies the principle that fair value should be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. Under SFAS No. 157, fair value measurements would be separately disclosed by level within the fair value hierarchy. SFAS No. 157 is effective for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. The Company's management is currently reviewing this new standard to determine its effects, if any, on our financial position, results of operations or cash flows.

In February 2007, the FASB issued SFAS No. 159, which provides entities with an option to report selected financial assets and liabilities at fair value. SFAS No. 159 also establishes presentation and disclosure requirements designed to facilitate comparisons between entities that choose different measurement attributes for similar types of assets and liabilities. This Statement is effective as of the beginning of the first fiscal year that begins after November 15, 2007. The Company's management is currently evaluating the impact that SFAS No. 159 will have on its consolidated financial statements.

13. CURRENT FINANCIAL CONDITION

Several factors have contributed to the Company's current financial condition:

- The impact of several material non-recurring events, including the one-time impairment of goodwill, the accrual of deferred compensation related to the employment contract of the Company's founder and then CEO, the implementation of a free trial program, the write off of the Company's deferred tax asset, and a lease abandonment charge related to the abandonment of the executive offices;
- Excessive expenses incurred in the Heartland operations; and
- Recurring losses due to the FDA's ban on ephedra products.

The Company has taken the following steps to significantly reduce its cost of sales and marketing, distribution and administrative costs:

- Reductions in force, encompassing all departments within the Company;
- The termination of a discount sales program, designed to give customers a cash discount after purchasing a certain dollar amount of product; and
- The termination of several extra employee benefits, including vehicle allowances and social and country-club privileges.

On March 31, 2006, we adopted a plan to cease the Heartland operations. We included an accrual for discontinued operations in the first quarter of 2006. On November 15, 2006, we entered into certain lease and purchase agreements with Republic Plastics Ltd. allowing Republic to take over operation of the Heartland plant immediately. Republic produces Styrofoam products for private label users. Pursuant to the Agreements, and effective November 15, 2006, Republic assumed the existing lease for the Heartland plant, purchased all remaining cup contracts with Heartland customers, and executed a two-year equipment lease. The equipment lease includes an option in favor of Republic to

purchase all the equipment utilized in the Heartland operations at a specified price. The option period begins November 15, 2007 and ends November 15, 2008. We are also exploring strategic acquisitions of network marketing companies with profitable, sustained operations.

The Company is seeing positive upswings and trends in associate recruiting. At March 31, 2007, our ratios compared to net sales are trending toward the levels that existed in our last profitable year.

AMS HEALTH SCIENCES, INC. AND SUBSIDIARIES

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006
(UNAUDITED)**

Finally, we introduced a new product offering, SABA, in February 2007 that we believe will be the replacement for the ephedra product banned in 2004.

On June 28, 2006, the Company completed a \$2,000,000 private placement financing through the sale of secured convertible notes to Laurus Master Fund Ltd. The net proceeds of the funding were used primarily for sales and marketing. For a full description of the terms of the note, see Note 6 to Consolidated Financial Statements.

14. CORRECTION OF ERROR IN REPORTING NET SALES

In the fourth quarter of 2006 it was discovered that the net sales were not being recorded correctly due to an error in system reports. The error was corrected and an adjustment was made in the fourth quarter of 2006. The comparative figures for 2006 have been changed to reflect this correction of error in the financial statements for the quarter ended March 31, 2007.

The comparative figures based on the quarterly adjustments in 2006 are as follows:

	2006 Quarters Ended,		
	March 31,	June 30,	September 30,
Net Sales	\$ 2,351,713	\$ 2,397,975	\$ 2,323,583
Adjustment	73,761	82,900	86,668
Adjusted net sales	\$ 2,425,474	\$ 2,480,875	\$ 2,410,251
Net loss from operations as previously reported	\$ (316,314)	\$ (152,900)	\$ (635,774)
Adjusted net loss from operations	\$ (242,553)	\$ (70,000)	\$ (549,106)

15. RECLASSIFICATIONS

Certain reclassifications of the prior year amounts have been made in order to provide comparability with the current presentation. These changes were made for presentation purposes only and did not have any effect on previously reported results of operations or equity.

Report of Independent Registered Public Accounting Firm

Board of Directors and Stockholders
AMS Health Sciences, Inc. and Subsidiaries

We have reviewed the accompanying consolidated balance sheet of AMS Health Sciences, Inc. and Subsidiaries as of March 31, 2007, and the related consolidated statements of operations and cash flows for the three month periods ended March 31, 2007 and 2006. These financial statements are the responsibility of the Company's management.

We conducted our review in accordance with standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the consolidated financial statements, as of and for the period ended March 31, 2007 and 2006, for them to be in conformity with accounting principles generally accepted in the United States of America.

We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of AMS Health Sciences, Inc. and Subsidiaries as of December 31, 2006 and the consolidated statements of operations, stockholders' equity and cash flows for the year then ended (not presented herein) and, in our report dated March 29, 2007, we expressed an unqualified opinion on those statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of December 31, 2006 is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

/S/ COLE & REED P.C.

Oklahoma City, Oklahoma
May 10, 2007

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

General

We market a product line consisting of approximately sixty products in three categories; weight management, dietary supplement and personal care products. These products are marketed through a network marketing organization in which independent associates purchase products for resale to retail customers as well as for their own personal use.

On September 9, 2005, we entered into a definitive Stock Purchase Agreement with Heartland and its principal shareholder for the purchase of all of the principal shareholder's stock in Heartland. Upon closing of the Stock Purchase Agreement, we acquired 2,000,000 shares, or approximately 83% of the outstanding capital stock of Heartland, for 200,000 shares of our common stock. In addition, we paid approximately \$200,000 to acquire the remaining shares of Heartland.

As described in Footnote 13 to the Financial Statements, we have made the decision to sell or cease operations at Heartland Cup. As such, our consolidated financial statements reflect Heartland Cup as a discontinued operation. As described in Part II, Item 1. Legal Proceedings, we have filed suit against Truett McCarty in the District Court of Oklahoma County, State of Oklahoma relating to our acquisition of Heartland. We believe that Mr. McCarty has both defrauded us regarding the financial conditions and results of operations of Heartland, as well as breached certain representations and warranties in the Stock Purchase Agreement relating to the Heartland acquisition. It is our belief that, had we been aware of the true facts and circumstances regarding Heartland's financial condition and historical results of operations, we would not have purchased Heartland. We presently believe that the dedication of our time and attention to Heartland is neither in our or our stockholders' best interests. As a result, we have discontinued the Heartland operations. On November 15, 2006, we entered into certain lease and purchase agreements with Republic Plastics Ltd. ("Republic"), allowing Republic to take over operation of the Heartland plant immediately. Republic produces Styrofoam products for private label users. Pursuant to the agreements, and effective November 15, 2006, Republic assumed the existing lease for the Heartland plant, purchased all remaining cup contracts with Heartland customers, and executed a two-year equipment lease. The equipment lease includes an option in favor of Republic to purchase all the equipment utilized in the Heartland operations at a specified price. The option period begins November 15, 2007 and ends November 15, 2008. Due to the above reasons, any further discussion of Heartland and its operations in this report will be limited to the discussions included in Part I, Item 2. Management's Discussion and Analysis or Plan of Operation and Part II, Item 1. Legal Proceedings.

On July 28, 2006, our Chief Executive Officer, outlined a strategic plan for our future operations as follows:

Sell Heartland Cup

- Use additional capital to build a foundation that will allow us to grow. Because of our consecutive years of losses, we have not had the funds to develop marketing, training and support tools, and programs to support our independent associates' efforts in the field. On June 28, 2006, we raised \$2,000,000 in additional financing. We used these funds to start an aggressive sales and marketing campaign, which we believe will increase our top line revenues. We intend to produce better product videos, business builder videos, printed material and other materials for use by our independent associates in their marketing efforts. In addition we intend to upgrade our back office to provide our independent associates with the most current management tools available in network marketing.
- Establish a new binary commission system and allow our independent associates to choose to use our existing commission system or the new binary commission system depending on their primary method of generating revenues. This will allow our independent associates to tailor their commission system to their operating methods.

Enter the international markets.

Critical Accounting Policies. We prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States, which require us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the year. Actual results could differ from those estimates. We consider the following policies to be most critical in understanding the judgments that are involved in preparing our financial statements and the uncertainties that could impact our results of operations, financial condition and cash flows.

Throughout this report, “net sales” represents the gross sales amounts reflected on our invoices to our associates, less associate discounts and sales returns. All of our products include a customer satisfaction guarantee. Our products may be returned within 30 days of purchase for a full refund or credit toward the purchase of another product. We also have a buy-back program whereby we repurchase products sold to an independent associate (subject to a restocking fee), provided the associate terminates his/her associateship agreement with us and returns the product within 12 months of original purchase in marketable condition. We receive our net sales price in cash or through credit card payments upon receipt of orders from associates.

Our “gross profit” consists of net sales less:

- Commissions and bonuses, consisting of commission payments to associates based on their current associate level within their organization, and other one-time incentive cash bonuses to qualifying associates;
- Cost of products, consisting of the prices we pay to our manufacturers for products, and royalty overrides earned by qualifying associates on sales within their associate organizations; and
- Cost of shipping, consisting of costs related to shipments, duties and tariffs, freight expenses relating to shipment of products to associates and similar expenses.

We recognize revenue upon shipment of products, training aids and promotional material to our independent associates. All of our customers pay for sales in advance of shipment. As such, we have no trade receivables. We used to make loans to associates, which were repayable in five years or less, and which were secured by commissions controlled by us. Associate loans are no longer allowed. Interest rates on loans were typically two percent or more above the Prime rate and were fixed. All loans were secured by guaranteed payment sources that were within our control, but subject to increases and decreases depending upon associate sales activity. Management determined that there was a possibility of default on the associate loans. As such, we have reserved an allowance for doubtful accounts in connection with the associate loans. At March 31, 2007, the allowance was approximately \$117,000. Total associate loans still outstanding at March 31, 2007 totaled approximately \$154,000.

In July 2001, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 142, “Goodwill and Other Intangible Assets”. This standard requires companies to stop amortizing existing goodwill and intangible assets with indefinite lives effective January 1, 2002. Under the new rules, companies would only adjust the carrying amount of goodwill or indefinite life intangible assets upon an impairment of the goodwill or indefinite life intangible assets. Our intangible assets consist of non-compete covenants and other intangibles, which have a significant residual value. These intangible assets are being amortized over the life of the contracts. We evaluate all intangible assets annually for indicators of impairment.

We use an asset and liability approach to account for income taxes. Deferred income taxes are recognized for the tax consequences of temporary differences and carryforwards by applying enacted tax rates applicable to future years to differences between the financial statement amounts and the tax bases of existing assets and liabilities. A valuation allowance is established if, in management's opinion, it is more likely than not that some portion of the deferred tax asset will not be realized. All evidence, both positive and negative, is considered to determine whether a valuation allowance is needed for some or all of a deferred tax asset. Judgment must be used in considering the relative impact of negative and positive evidence. The more negative evidence that exists, (a) the more positive evidence is necessary and (b) the more difficult it is to support a conclusion that a valuation allowance is not needed. Based on the above factors and management's evaluation, we determined at December 31, 2004, that a valuation allowance should be established for our entire deferred tax asset, which was approximately \$6,000,000 at March 31, 2007.

We write down our inventory to provide for estimated obsolete or unsalable inventory based on assumptions about future demand for our products and market conditions. If future demand and market conditions are less favorable than

management's assumptions, additional inventory write-downs could be required. Likewise, favorable future demand and market conditions could positively impact future operating results if written-off inventory is sold. At March 31, 2007, we have a marketing inventory obsolescence reserve of approximately \$51,000 for estimated obsolete or unsalable inventory.

-22-

We account for contingencies in accordance with SFAS No. 5, "Accounting for Contingencies". SFAS 5 requires that we record an estimated loss from a loss contingency when information available prior to issuance of our financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements, and the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and income tax matters requires us to use our judgment. Many legal and tax contingencies can take years to resolve. Generally, as the time period increases over which the uncertainties are resolved, the likelihood of changes to the estimate of the ultimate outcome increases. However, an adverse outcome in these matters could have a material impact on our results of operations, financial condition and cash flows.

Results of Operations

The following table sets forth, in dollars and as a percentage of net sales, selected results of operations for the three months ended March 31, 2007 and 2006. The selected results of operations are derived from our unaudited consolidated financial statements. The results of operations for the periods presented are not necessarily indicative of our future operations.

	For the Three Months Ended			
	March 31,			
	2007		2006	
	Amount	Percent	Amount	Percent
Net sales	\$ 2,435,342	100.0%	\$ 2,425,474	100.0%
Cost of Sales:				
Commissions and bonuses	804,945	33.1	827,815	34.1
Cost of products	482,302	19.8	458,070	18.9
Cost of shipping	269,458	11.1	279,269	11.5
Total cost of sales	1,556,705	63.9	1,565,154	64.5
Gross profit	878,637	36.1	860,320	35.5
Marketing, distribution and administrative expenses:				
Marketing	282,996	11.6	141,144	5.8
Distribution and administrative	897,465	36.9	689,520	28.4
Total marketing, distribution and administrative expenses	1,180,461	48.5	830,664	34.2
Income (loss) from operations	(301,824)	(12.4)	29,656	1.2
Other income (expense):				
Interest and dividends, net	(143,174)	(5.9)	3,842	0.2
Other income (expense)	27,005	1.1	59,664	2.4
Total other income (expense)	(116,169)	(4.8)	63,506	2.6
Income (loss) from continuing operations before taxes	(417,993)	(17.2)	93,162	3.8
Income tax	-	-	-	-
Income (loss) from continuing operations	(417,993)	(17.2)	93,162	3.8
Discontinued operations:				

Edgar Filing: AMS HEALTH SCIENCES INC - Form 10QSB

Income (loss) from operations of Heartland Cup	7,654	0.3	(335,715)	(13.8)
Income tax benefit	-	-	-	-
Income (loss) from discontinued operations	7,654	0.3	(335,715)	(13.8)
Net loss	\$ (410,339)	(16.8)%	\$ (242,553)	(10.0)%

Comparison of the Three Months ended March 31, 2007 and 2006

Our net sales during the three months ended March 31, 2007 increased \$9,868 or .4%, to \$2,435,342 from \$2,425,474 during the three months ended March 31, 2006. Due to the correction of an error, the net sales for the three months ended March 31, 2006 increased by \$73,761 from \$2,351,713 to \$2,425,474. See Part I, Note 16 for a description of the reported change.

In late February 2007, we launched a new division and product. Saba weight loss features the Borojo fruit, a fruit which offers essential amino acids for the body, as well as our exclusive formula of adaptogens, which help diminish the impact of physical, mental and emotional stress. Saba weight loss accounted for \$92,600 of the first quarter net sales.

Our cost of sales during the three months ended March 31, 2007 decreased \$8,449, or .5%, to \$1,556,705 from \$1,565,154 during the same period in 2006. Total cost of sales, as a percentage of net sales, decreased to 63.9% during the three months ended March 31, 2007 from 64.5% during the same period in 2006. The decrease in cost of sales resulted from:

- A decrease of approximately \$22,900 in associate commissions and bonuses; and

- A decrease of approximately \$10,000 in the shipping costs.

The decrease in cost of sales was partially offset by:

- An increase of approximately \$24,000 in cost of products.

The factors discussed above resulted in an increase in gross profit of \$18,317, or 2.1%, to \$878,637 for the three months ended March 31, 2007 from \$860,320 for the same period in 2006.

Marketing expenses increased \$141,852, or 100.5%, to \$282,996 during the three months ended March 31, 2007, from \$141,144 during the same period in 2006. The increase in expense was primarily attributable to:

- An increase in promotional cost of approximately \$78,000, related primarily to the 2007 national convention; and
- An increase in professional services of approximately \$125,000 related to consulting fees for the branding of the new SABA division.

The increase in marketing expense was partially offset by:

- A decrease in employee costs of approximately \$37,000 related to reductions in staff; and

- A decrease in travel costs of approximately \$21,000 related to outside travel of marketing.

Administrative expense increased \$207,945 or 30.2%, to \$897,465 during the three months ended March 31, 2007 from \$689,520 during the same period of 2006. The increase in expense was primarily attributable to:

- An increase in employee costs of approximately \$103,000 related primarily to two additional executive headcount and vehicle allowance bonuses for executives;

An increase in professional expenses of approximately \$23,000 related to a consulting agreement and staff recruitment fees;

· An increase in amortization expense of approximately \$43,000 due to deferred financing costs related to the debt;

· An increase in promotional expenses of approximately \$37,000 related to website expenses; and

· An increase in general and administrative expense of approximately \$14,000 related to postage, supplies, telephone, etc.

The marketing and administrative expenses as a percentage of net sales increased to 36.9% during the three months ended March 31, 2007 from 28.4% during the same period in 2006.

Our net other income (reduced by other expense) decreased by \$179,675 to net other expense of (\$116,169) at March 31, 2007, from net other income of \$63,506 during the same period in 2006, primarily due to:

- A decrease in gain on sale of assets of approximately \$47,000 related to the sale of motorcoach and an excess vehicle in 2006; and
- An increase in interest expense of approximately \$161,000 related to the Laurus debt executed in 2006.

The decrease in net other income was partially offset by:

- A increase in interest income of approximately \$8,000 related to the notes receivables; and
- An increase in other income of approximately \$15,000 related to the collection of a class action suit settlement.

Our income (loss) from continuing operations before taxes decreased \$511,155 to a net loss of (\$417,993) for the three months ended March 31, 2007, compared to net income of \$93,162 during the same period in 2006. Income (loss) from continuing operations before taxes as a percentage of net sales was (17.2%) and 3.8% for the three months ended March 31, 2007 and 2006, respectively. Income tax benefit for the first quarter 2007 and 2006 was, \$0. Our net income (loss) from continuing operations decreased \$511,155 to net loss of (\$417,993) for the three months ended March 31, 2007, from net income of \$93,162 for the same period in 2006. This increase was attributable to:

- The increase in gross profit to \$878,637 during 2007 from \$860,320 during 2006;
- The increase in marketing and administrative expense to \$1,180,461 during 2007 from \$830,664 during 2006; and
- The decrease in other income (expense) to expense of (\$116,169) during 2007 from income of \$63,506 during 2006.

Net income (loss) from continuing operations as a percentage of net sales decreased to (17.2%) for the three months ended March 31, 2007, from 3.8% during the same period in 2006.

Net loss increased \$167,786 to \$410,339 for the three months ended March 31, 2007, compared to \$242,553 for the same period of 2006. This increase was primarily the result of amortization of the valuation discount and deferred financing costs related to the financing closed in the second quarter of 2006.

Seasonality

No pattern of seasonal fluctuations exists due to the patterns that we are currently experiencing. However, there is no assurance that we will not become subject to seasonal fluctuations in operations.

Recently Issued Accounting Standards

In June 2006, the FASB issued interpretation No. 48, Accounting for Uncertainty in Income Taxes—an Interpretation of FASB statement No. 109, (“FIN 48”). FIN 48 clarifies the accounting for uncertainty in income taxes recognized in a company’s financial statements in accordance with SFAS No. 109, Accounting for Income Taxes. FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. FIN 48 is effective for fiscal years beginning after December 15, 2006. The Company has evaluated the impact of FIN 48 as of the January 1, 2007 adoption date and determined there will be no impact to its financial statements.

In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements.” SFAS No. 157 clarifies the principle that fair value should be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. Under SFAS No. 157, fair value measurements would be separately disclosed by level within the fair value hierarchy. SFAS No. 157 is effective for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. The Company’s management is currently reviewing this new standard to determine its effects, if any, on our financial position, results of operations or cash flows.

In February 2007, the FASB issued SFAS No. 159, which provides entities with an option to report selected financial assets and liabilities at fair value. SFAS No. 159 also establishes presentation and disclosure requirements designed to facilitate comparisons between entities that choose different measurement attributes for similar types of assets and liabilities. This Statement is effective as of the beginning of the first fiscal year that begins after November 15, 2007. The Company’s management is currently evaluating the impact that SFAS No. 159 will have on its consolidated financial statements.

Liquidity and Capital Resources

Our primary source of liquidity has been cash provided by sales of our common stock and marketable securities. At March 31, 2007, we had a working capital deficit of (\$738,505), compared to a working capital deficit of (\$252,426) at December 31, 2006. Our working capital needs over the next 12 months consist primarily of marketing and administrative expenses and debt service requirements. As discussed below and in Note 5 of the Notes to the Consolidated Financial Statements, we will be required to make principal payments on the Laurus debt beginning on July 1, 2007, in the amount of \$83,333 per month, in addition to the monthly payments of interest that we have been making since July 2006. If certain criteria are met, Laurus is required under the terms of the Note to convert the principal and interest payments into share of our common stock, at a price of \$0.51 per share, with no effect on cash flow. To the extent that such conditions are not met, however, or are only partially met, we will be required to make the payments of principal and interest, or some portion thereof, in cash. Additionally, certain restrictions exist on Laurus’ ability to convert the Note into our common stock. Most importantly, Laurus is prohibited from converting the Note or exercising its Warrant if such conversion would result in Laurus beneficially owning more than 4.99% of our common stock. Laurus can waive this restriction upon 61 days’ notice to us. Additionally, this restriction becomes automatically null and void upon an event of default under the Note.

Management believes our working capital needs over the next 12 months will be provided by our operating activities and existing cash and cash equivalents. During the three months ended March 31, 2007, net cash used in operating activities was (\$221,668), net cash provided by investing activities was \$287,985 and net cash used in financing activities was (\$112,656). This represented a net decrease in cash during the period of (\$46,339).

The following have contributed to our current cash and cash equivalent position:

- Excessive expenses incurred in the Heartland operations; and
- Recurring losses due to the FDA's ban on ephedra products.

We have taken the following steps to significantly reduce our cost of sales and marketing, distribution and administrative costs:

- Reductions in force, encompassing all departments within the Company;

- The termination of a discount sales program, designed to give customers a cash discount after purchasing a certain dollar amount of product; and
- The termination of several extra employee benefits, including vehicle allowances and social and country-club privileges.

On March 31, 2006, we adopted a plan to cease the Heartland operations. We included an accrual for discontinued operations in the first quarter of 2006. On November 15, 2006, we entered into certain lease and purchase agreements with Republic Plastics Ltd. allowing Republic to take over operation of the Heartland plant immediately. Republic produces Styrofoam products for private label users. Pursuant to the Agreements, and effective November 15, 2006, Republic assumed the existing lease for the Heartland plant, purchased all remaining cup contracts with Heartland customers, and executed a two-year equipment lease. The equipment lease includes an option in favor of Republic to purchase all the equipment utilized in the Heartland operations at a specified price. The option period begins November 15, 2007 and ends November 15, 2008. We are also exploring strategic acquisitions of network marketing companies with profitable, sustained operations.

On June 28, 2006, the Company entered into a series of agreements with Laurus Master Fund, Ltd. (“Laurus”) whereby the Company issued to Laurus (i) a secured convertible term note (“Note”) in the principal amount of \$2,000,000, and (ii) a warrant (“Warrant”) to purchase up to 2,272,727 shares of the Company’s common stock at a price of \$0.53 per share. Out of the loan proceeds, the Company agreed to pay the sum of \$74,000 to Laurus Capital Management, LLC, the investment advisor to Laurus, the sum of \$27,500 to Laurus Capital Management, LLC as reimbursement for its due diligence and legal fees and expenses incurred in connection with the transaction, and the sum of \$1,500 to Loeb & Loeb LLP, the escrow agent for Laurus. Total closing costs were \$103,000.

The principal amount of the Note bears interest at a per annum rate equal to the prime rate (as published in the Wall Street Journal from time to time) plus three percent (3.0%); provided, however that the interest rate may not be less than ten percent (10.0%). At March 31, 2007, the interest rate was 11.25%. Interest payments are due monthly beginning July 1, 2006. Principal payments in the amount of \$83,333 are due monthly beginning July 1, 2007. The final maturity date of the Note is June 28, 2009 (the “Maturity Date”). Interest expense related to the note was \$51,775 for the three months ended March 31, 2007.

The principal amount of the Note and accrued interest thereon is convertible into shares of the Company’s common stock at a price of \$0.51 per share, subject to anti-dilution adjustments. Under the terms of the Note, the monthly payments of interest and/or principal (the “Monthly Amount”) due on the Note are payable in shares of the Company’s common stock if the following criteria are met: (i) the average closing price of the Company’s common stock for the five (5) days preceding the payment date is greater than or equal to 115% of the Fixed Conversion Price (defined below) and (ii) the amount of such conversion does not exceed twenty five percent (25%) of the aggregate dollar trading volume of the Company’s common stock for the period of twenty-two trading days immediately preceding such payment date. If subsection (i) above is met but subsection (ii) above is not met as to the entire Monthly Amount, then Laurus is required to convert only such part of the Monthly Amount that meets the criteria of subsection (ii). The Company has agreed to register all of the shares that are issuable upon conversion of the Note and exercise of the 2,272,727 Warrants. The Company has granted Laurus a right of first refusal with respect to any debt or equity financings.

We can prepay the Note (an “Optional Redemption”) by paying Laurus (i) 125% of the principal amount outstanding if the Optional Redemption occurs prior to the June 28, 2007, (ii) 120% of the principal amount outstanding if the Optional Redemption occurs after June 28, 2007 and prior to the June 28, 2008, and (iii) 115% of the principal amount outstanding if the Optional Redemption occurs after June 28, 2008 and prior to the Maturity Date.

The Company calculated that the fair value of the Warrants issued to Laurus was \$588,452 based upon the relative value of the Black-Scholes valuation of the warrants and the underlying debt amount. The Company determined that the beneficial conversion feature ("BCF") of the note was \$588,452. The value of the warrants issued to Laurus of \$588,452 and the \$588,452 of calculated BCF have been reflected by the Company as a valuation discount and offset to the face amounts of the Notes. The valuation discount will be amortized into interest expense over the three-year term of the note using the effective interest method. Amortization of discounts for the conversion feature and the warrants resulted in charges to interest expense totaling \$104,878 for the three months ended March 31, 2007.

In conjunction with the financing, the Company also incurred fees to various investment advisors that facilitated the transaction. These fees totaled \$287,500, of which \$127,500 was paid through the issuance of 250,000 shares of our common stock. In addition, the Company issued these advisors warrants to purchase 495,543 shares of common stock at a price of \$0.51 per share. The Company calculated that the fair value of the warrants issued to the advisors was \$130,770 based upon the relative value of the Black-Scholes valuation of the warrants and the underlying debt amount. The closing costs, fees paid to the advisors, and the value of the warrants issued to the advisors have been reflected as deferred financing costs in the accompanying balance sheet and are being amortized over the life of the loan. Amortization of the deferred financing costs related to the note totaled \$43,439, for the three months ended March 31, 2007.

Item 3. CONTROLS AND PROCEDURES

As of the end of the period covered by this report, an evaluation was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as required by Rule 13a-15(b). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that these disclosure controls and procedures were effective. There have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

We are a defendant in a lawsuit commenced against us in September 2006 entitled, Janet and Royce Britt v. AMS Health Science, Inc., Case No. 5:06-cv-01005-F, which was filed in the United States District Court for the Western District of Oklahoma. The Britts asserted a breach of contract claim alleging that they sold their stock in Chambre' International, Inc. to us in 1997 in exchange for our common stock and an employment agreement for Mrs. Britt. Under the alleged employment agreement, Mrs. Britt contended she was to receive a salary and certain benefits that could not be terminated unilaterally by us. We discontinued Mrs. Britt's salary and benefits and the Britts commenced the above-mentioned lawsuit for breach of contract seeking past and future payment for the salary and benefits lost. We settled this matter by agreement dated March 1, 2007. All claims and causes of action have been dismissed with prejudice to re-filing. Pursuant to the terms of the settlement agreement, we entered into a distribution agreement with Britt Enterprises, Inc. regarding the sale and distribution of Chambre's products.

On February 6, 2006, AMS Health Sciences, Inc. and AMS Manufacturing, Inc. filed a lawsuit against Truett McCarty. AMS Health Sciences, Inc. and AMS Manufacturing, Inc. v. Truett McCarty, District Court of Oklahoma County, State of Oklahoma, Case No. CJ-2006-981. We allege that Mr. McCarty defrauded us in the sale of his stock in Heartland by failing to disclose the true amount of Heartland's accounts payable and a certain long-term liability of Heartland. In addition, we allege that this failure was a breach of the stock purchase agreement Mr. McCarty signed with us. Mr. McCarty has filed an answer denying our allegations. In addition, Mr. McCarty has alleged several counterclaims against us. Mr. McCarty has alleged we defrauded him with regard to the value of the stock he received in exchange for his interest in Heartland that we breached the terms of the stock purchase agreement by failing to take steps to remove Mr. McCarty as guarantor of a certain promissory notes, that we tortiously interfered with a promissory note between Mr. McCarty and Heartland and that we tortiously interfered with an employment agreement between Mr. McCarty and Heartland. Mr. McCarty has also sought to reform the stock purchase agreement in numerous respects, and to pierce the corporate veils of AMS Health Sciences, Inc. and AMS Manufacturing, Inc. in order to hold them liable for any breach by Heartland of the promissory note and employment agreement between Heartland and Mr. McCarty. In addition, Mr. McCarty has brought claims against Heartland for breach of the promissory note and employment agreement. We deny liability to Mr. McCarty and will vigorously defend these counterclaims. The parties are engaged in written discovery and depositions. A pretrial conference will occur on July 12, 2007, at which time it is likely that the court will set a trial date.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None

Item 3. DEFAULTS UPON SENIOR SECURITIES

None

Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None

Item 5. OTHER INFORMATION

None

Item 6. EXHIBITS

(a) Exhibits

- 3.1 The Registrant's Certificate of Incorporation, incorporated by reference to the Registration Statement on Form SB-2 (Registration No. 333-47801) filed with the Commission on March 11, 1998.
- 3.2 The Registrant's Bylaws, incorporated by reference to the Registration Statement on Form SB-2 (Registration No. 333-47801) filed with the Commission on March 11, 1998.
- 10.1 Stock Option Agreement of Advantage Marketing Systems dated January 3, 2001, incorporated by reference to Form 8-K filed with the Commission on January 8, 2001.
- 10.2* The Advantage Marketing Systems, Inc. 1995 Stock Option Plan, incorporated by reference to Form SB-2 Registration Statement (No. 33-80629), filed with the Commission on November 20, 1996.
- 10.3* Employment Agreement by and between Steven G. Kochen and Registrant dated effective as of August 9, 2005, incorporated by reference to Form 8-K filed with the Commission on August 12, 2005.
- 10.4* Employment Agreement by and between Jerry W. Grizzle and Registrant dated effective as of January 25, 2006, incorporated by reference to Form 10-KSB filed with the Commission on April 3, 2006.
- 10.5* Employment Agreement by and between Robin L. Jacob and Registrant dated effective as of February 12, 2006, incorporated by reference to Form 8-K filed with the Commission on April 12, 2006.
- 10.6 Consulting Agreement by and between TVC Consulting and Registrant dated effective as of March 1, 2006, incorporated by reference to Form 10-QSB filed with the Commission on May 15, 2006
- 10.7 Securities Purchase Agreement dated June 28, 2006 by and between the Company and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.8 Secured Convertible Term Note dated June 28, 2006 by the Company in favor of Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.9 Common Stock Purchase Warrant dated June 29, 2006 by the Company in favor of Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.10 Registration Rights Agreement dated June 28, 2006 by and between the Company and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.11 Stock Pledge Agreement dated June 28, 2006 by and among the Company, AMS Manufacturing, Inc. and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.12 Master Security Agreement dated June 28, 2006 by and among the Company, AMS Manufacturing, Inc. and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.13

Edgar Filing: AMS HEALTH SCIENCES INC - Form 10QSB

Mortgage dated June 28, 2006 by and between the Company and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.

10.14 Grant of Security Interest in Patents and Trademarks dated June 28, 2006 by and between the Company and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.

10.15 Common Stock Purchase Warrant dated June 28, 2006 by the Company in favor of Ascendant Securities, LLC, incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.

-30-

10.16 Engagement Letter between the Company and Ascendant Securities, LLC, incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.

10.17* Employment Agreement by and between Dennis P. Loney and Registrant dated effective as of September 19, 2006, incorporated by reference to Form 8-K filed with the Commission on September 25, 2006.

15 Letter of independent accountants as to unaudited interim financial information, filed herewith.

31.1 Chief Executive Officer Certification, filed herewith.

31.2 Chief Financial Officer Certification, filed herewith.

32.1 Section 1350 Certification of our Chief Executive Officer, filed herewith.

32.2 Section 1350 Certification of our Chief Financial Officer, filed herewith.

* Designates a compensatory plan.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

REGISTRANT:
AMS HEALTH SCIENCES,
INC.

Dated: May 10, 2007

By: /S/ ROBIN L. JACOB
Robin L. Jacob, Vice President
and Chief
Financial Officer
(Duly Authorized Officer of
Registrant and
Principal Financial Officer)

Index of Exhibits

- 3.1 The Registrant's Certificate of Incorporation, incorporated by reference to the Registration Statement on Form SB-2 (Registration No. 333-47801) filed with the Commission on March 11, 1998.
- 3.2 The Registrant's Bylaws, incorporated by reference to the Registration Statement on Form SB-2 (Registration No. 333-47801) filed with the Commission on March 11, 1998.
- 10.1 Stock Option Agreement of Advantage Marketing Systems dated January 3, 2001, incorporated by reference to Form 8-K filed with the Commission on January 8, 2001.
- 10.2* The Advantage Marketing Systems, Inc. 1995 Stock Option Plan, incorporated by reference to Form SB-2 Registration Statement (No. 33-80629), filed with the Commission on November 20, 1996.
- 10.3* Employment Agreement by and between Steven G. Kochen and Registrant dated effective as of August 9, 2005, incorporated by reference to Form 8-K filed with the Commission on August 12, 2005.
- 10.4* Employment Agreement by and between Jerry W. Grizzle and Registrant dated effective as of January 25, 2006, incorporated by reference to Form 10-KSB filed with the Commission on April 3, 2006.
- 10.5* Employment Agreement by and between Robin L. Jacob and Registrant dated effective as of February 12, 2006, incorporated by reference to Form 8-K filed with the Commission on April 12, 2006.
- 10.6 Consulting Agreement by and between TVC Consulting and Registrant dated effective as of March 1, 2006, incorporated by reference to Form 10-QSB filed with the Commission on May 15, 2006.
- 10.7 Securities Purchase Agreement dated June 28, 2006 by and between the Company and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.8 Secured Convertible Term Note dated June 28, 2006 by the Company in favor of Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.9 Common Stock Purchase Warrant dated June 29, 2006 by the Company in favor of Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.10 Registration Rights Agreement dated June 28, 2006 by and between the Company and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.11 Stock Pledge Agreement dated June 28, 2006 by and among the Company, AMS Manufacturing, Inc. and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.12 Master Security Agreement dated June 28, 2006 by and among the Company, AMS Manufacturing, Inc. and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.
- 10.13 Mortgage dated June 28, 2006 by and between the Company and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.

Edgar Filing: AMS HEALTH SCIENCES INC - Form 10QSB

10.14 Grant of Security Interest in Patents and Trademarks dated June 28, 2006 by and between the Company and Laurus Master Fund, Ltd., incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.

10.15 Common Stock Purchase Warrant dated June 28, 2006 by the Company in favor of Ascendant Securities, LLC, incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.

-33-

10.16 Engagement Letter between the Company and Ascendant Securities, LLC, incorporated by reference to the Form 10-QSB filed with the Commission on August 14, 2006.

10.17* Employment Agreement by and between Dennis P. Loney and Registrant dated effective as of September 19, 2006, incorporated by reference to Form 8-K filed with the Commission on September 25, 2006.

15 Letter of independent accountants as to unaudited interim financial information, filed herewith.

31.1 Chief Executive Officer Certification, filed herewith.

31.2 Chief Financial Officer Certification, filed herewith.

32.1 Section 1350 Certification of our Chief Executive Officer, filed herewith.

32.2 Section 1350 Certification of our Chief Financial Officer, filed herewith.

* Designates a compensatory plan.

